Your activity: 6 p.v.

Rosiglitazone (United States: Not available): Drug information

Rosiglitazone (United States: Not available): Drug information
(For additional information see "Rosiglitazone (United States: Not available): Patient drug information" and see "Rosiglitazone (United States: Not available): Pediatric drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
ALERT: US Boxed Warning
Congestive heart failure:

Thiazolidinediones, including rosiglitazone, cause or exacerbate congestive heart failure (CHF) in some patients. After initiation of rosiglitazone and after dose increases, observe patients carefully for signs and symptoms of heart failure (including excessive, rapid weight gain; dyspnea; and/or edema). If these signs and symptoms develop, manage the heart failure according to current standards of care. Furthermore, consider discontinuation or dose reduction of rosiglitazone.

Rosiglitazone is not recommended in patients with symptomatic heart failure. Initiation of rosiglitazone in patients with established New York Heart Association (NYHA) class III or IV heart failure is contraindicated.

Myocardial infarction:

A meta-analysis of 52 clinical trials (mean duration, 6 months; 16,995 total patients), most of which compared rosiglitazone with placebo, showed rosiglitazone to be associated with a statistically significant increased risk of myocardial infarction (MI). Three other trials (mean duration, 46 months; 14,067 total patients) comparing rosiglitazone with some other approved oral antidiabetic agents or placebo showed a statistically nonsignificant increased risk of MI and a statistically nonsignificant decreased risk of death. There have been no clinical trials directly comparing the cardiovascular risk of rosiglitazone and pioglitazone, another thiazolidinedione, but in a separate trial, pioglitazone (when compared with placebo) did not show an increased risk of MI or death.

Brand Names: US
  • Avandia [DSC]
Brand Names: Canada
  • Avandia [DSC]
Pharmacologic Category
  • Antidiabetic Agent, Thiazolidinedione
Dosing: Adult

Note: Avandia has been discontinued in the United States for >1 year.

Note: May require a dose reduction of insulin secretagogues (sulfonylureas, meglitinides) to avoid hypoglycemia; consider stopping insulin or reducing insulin dose (ADA/EASD [Davies 2018]; manufacturer's labeling).

Diabetes mellitus, type 2, treatment

Diabetes mellitus, type 2, treatment:

Note: May be used as an adjunctive agent or alternative monotherapy for select patients, including those in whom initial therapy with lifestyle intervention and metformin failed, or cannot take metformin, particularly when avoidance of hypoglycemia is desirable. Pioglitazone may have a more favorable cardiovascular profile compared to rosiglitazone; use of any thiazolidinedione has been associated with an increased risk of heart failure, and risk is increased with concomitant insulin use (AACE/ACE [Garber 2020]; ADA 2021).

Oral: Initial: 4 mg/day as a single dose or in 2 divided doses If response is inadequate after 8 to 12 weeks of treatment, the dosage may be increased to 8 mg/day as a single dose or in 2 divided doses daily; maximum dose: 8 mg/day. Per some clinical trial data, 4 mg twice daily may lower fasting plasma glucose and HbA1c more effectively than 8 mg once daily.

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Adult

No dosage adjustment necessary.

Dosing: Hepatic Impairment: Adult

Hepatic impairment prior to initiation: There are no dosage adjustments provided in the manufacturer's labeling. Clearance is significantly lower in hepatic impairment; therapy should not be initiated if the patient exhibits active liver disease or increased transaminases (ALT >2.5 times the upper limit of normal) at baseline.

Hepatic impairment during therapy: Discontinue therapy if ALT is persistently >3 times ULN or jaundice occurs.

Dosing: Pediatric

(For additional information see "Rosiglitazone (United States: Not available): Pediatric drug information")

Note: Avandia has been discontinued in the United States for >1 year.

Diabetes mellitus, type 2

Diabetes mellitus, type 2: Limited data available: Note: Rosiglitazone is not recommended for the management of type 2 diabetes mellitus (T2DM) in children and adolescents; if thiazolidinedione therapy is required, other agents are preferred (ADA 2022b; ISPAD [Shah 2022]).

Children ≥10 years and Adolescents: Oral: Initial: 2 mg twice daily; then increase to 4 mg twice daily after 8 weeks. Dosing presented was used in 233 pediatric patients as part of a larger multicenter comparative trial of treatments (n=699) in which rosiglitazone in combination with metformin was more effective than metformin alone or metformin and lifestyle changes at maintaining glycemic control (Copeland 2011; TODAY Study Group 2007; TODAY Study Group 2012).

Dosage adjustment for concomitant therapy: Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.

Dosing: Kidney Impairment: Pediatric

Based on experience in adults, no dosage adjustment necessary.

Dosing: Hepatic Impairment: Pediatric

Children ≥10 years and Adolescents:

Hepatic impairment prior to initiation: There are no dosage adjustments provided in the manufacturer's labeling. Clearance is significantly lower in hepatic impairment; based on recommendations in adults, therapy should not be initiated if the patient exhibits active liver disease or increased transaminases (ALT >2.5 times ULN) at baseline.

Hepatic impairment during therapy: Based on recommendations in adults, discontinue therapy if ALT is persistently >3 times ULN or jaundice occurs.

Dosing: Older Adult

Refer to adult dosing.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Avandia: 2 mg [DSC], 4 mg [DSC]

Generic Equivalent Available: US

No

Dosage Forms: Canada

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Tablet, Oral:

Avandia: 2 mg [DSC], 4 mg [DSC], 8 mg [DSC]

Generic: 2 mg, 4 mg, 8 mg

Product Availability

Avandia has been discontinued in the United States for >1 year.

Prescribing and Access Restrictions

Health Canada requires written informed consent for new and current patients receiving rosiglitazone.

Medication Guide and/or Vaccine Information Statement (VIS)

An FDA-approved patient medication guide, which is available with the product information and at http://www.fda.gov/downloads/Drugs/DrugSafety/ucm085922.pdf, must be dispensed with this medication.

Administration: Adult

Oral: May be administered without regard to meals.

Administration: Pediatric

Oral: May be taken without regard to meals.

Use: Labeled Indications

Diabetes mellitus, type 2, treatment: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

Medication Safety Issues
Sound-alike/look-alike issues:

Avandia may be confused with Avalide, Coumadin, Prandin

High alert medication:

This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes that have a heightened risk of causing significant patient harm when used in error.

International issues:

Avandia [US, Canada, and multiple international markets] may be confused with Avanza brand name for mirtazapine [Australia]

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Note: As reported in monotherapy studies; the rate of certain adverse reactions (eg, anemia, edema, hypoglycemia) may be higher with some combination therapies. Rare cases of hepatocellular injury have been reported in men in their 60s within 2 to 3 weeks after initiation of rosiglitazone therapy. LFTs in these patients revealed severe hepatocellular injury which responded with rapid improvement of liver function and resolution of symptoms upon discontinuation of rosiglitazone. Patients were also receiving other potentially hepatotoxic medications (Al-Salman 2000; Freid 2000).

>10%: Endocrine & metabolic: Increased HDL cholesterol, increased LDL cholesterol, increased serum cholesterol (total), weight gain

1% to 10%:

Cardiovascular: Edema (5%), hypertension (4%); cardiac failure (≤3% in patients receiving insulin; incidence likely higher in patients with pre-existing cardiac failure), ischemic heart disease (3%; incidence likely higher in patients with pre-existing CAD)

Central nervous system: Headache (6%)

Endocrine & metabolic: Hypoglycemia (1% to 3%; combination therapy with insulin: 12% to 14%)

Gastrointestinal: Diarrhea (3%)

Hematologic & oncologic: Anemia (2%)

Neuromuscular & skeletal: Bone fracture (≤9%; incidence greater in females; usually upper arm, hand, or foot), arthralgia (5%), back pain (4% to 5%)

Respiratory: Upper respiratory tract infection (4% to 10%), nasopharyngitis (6%)

Miscellaneous: Trauma (8%)

<1%, postmarketing, and/or case reports: Anaphylaxis, angina pectoris, angioedema, blurred vision, cardiac arrest, coronary artery disease, coronary thrombosis, decreased HDL cholesterol, decreased hematocrit, decreased hemoglobin, decreased visual acuity, decreased white blood cell count, dyspnea, hepatic failure, hepatitis, increased serum bilirubin, increased serum transaminases, jaundice (reversible), macular edema, myocardial infarction, pleural effusion, pruritus, pulmonary edema, skin rash, Stevens-Johnson syndrome, thrombocytopenia, urticaria, weight gain (rapid, excessive; usually due to fluid accumulation)

Contraindications

US labeling: Hypersensitivity to rosiglitazone or any component of the formulation; NYHA Class III/IV heart failure (initiation of therapy)

Canadian labeling: Hypersensitivity to rosiglitazone or any component of the formulation; any stage of heart failure (eg, NYHA Class I, II, III, IV); serious hepatic impairment; pregnancy

Warnings/Precautions

Concerns related to adverse effects:

• Edema: Dose-related edema may occur. Use with caution in patients with edema; may increase plasma volume and/or cause fluid retention. Monitor for signs/symptoms of heart failure.

• Fractures: Increased incidence of bone fractures in females treated with rosiglitazone was observed during analysis of long-term trial; majority of fractures occurred in the upper arm, hand and foot (differing from the hip or spine fractures usually associated with postmenopausal osteoporosis). Consider risk of fracture prior to initiation and during use.

• Heart failure/cardiac effects: [US Boxed Warning]: Thiazolidinediones, including rosiglitazone, may cause or exacerbate congestive heart failure; closely monitor for signs and symptoms of congestive heart failure (eg, rapid weight gain, dyspnea, edema), particularly after initiation or dose increases. If heart failure develops, treat accordingly and consider dose reduction or discontinuation. Not recommended for use in any patient with symptomatic heart failure. Initiation of therapy is contraindicated in patients with NYHA class III or IV heart failure. A higher frequency of cardiovascular events has been noted in patients with NYHA class I or II heart failure treated with rosiglitazone. Use may also be associated with an increased risk of angina and MI. Use with caution in patients at risk for cardiovascular events and monitor closely. Discontinue if any deterioration in cardiac status occurs.

• Hematologic effects: May decrease hemoglobin, hematocrit, and/or WBC count (slight); effects may be related to increased plasma volume and/or dose-related. Changes in hemoglobin and hematocrit generally occurred during the first 3 months after initiation of therapy and after dose increases. Use with caution in patients with anemia.

• Hypoglycemia: The risk of hypoglycemia is increased when rosiglitazone is combined with other hypoglycemic agents; dosage adjustment of concomitant hypoglycemic agents may be necessary.

• Macular edema: Has been reported with thiazolidinedione use, including rosiglitazone; some patients with macular edema presented with blurred vision or decreased visual acuity, and most had peripheral edema at time of diagnosis. In addition to regular ophthalmic exams, diabetic patients with visual symptoms should receive prompt ophthalmic evaluation. Improvement in macular edema may occur with discontinuation of therapy.

• Weight gain: Dose-related weight gain observed with use; mechanism unknown but likely associated with fluid retention and fat accumulation.

Disease-related concerns:

• Bariatric surgery:

– Altered absorption: Absorption may be altered given the anatomic and transit changes created by gastric bypass and sleeve gastrectomy surgery (Mechanick 2020; Melissas 2013).

– Weight gain: Evaluate risk vs benefit and consider alternative therapy after gastric bypass, sleeve gastrectomy, and gastric banding; weight gain may occur (Apovian 2015).

• Hepatic impairment: Use with caution in patients with elevated transaminases (AST or ALT); do not initiate in patients with active liver disease or ALT >2.5 times the upper limit of normal (ULN) at baseline; evaluate patients with ALT ≤2.5 times ULN at baseline or during therapy for cause of enzyme elevation; during therapy, if ALT >3 times ULN, reevaluate levels promptly and discontinue if elevation persists or if jaundice occurs at any time during use.

• Ischemic heart disease: Do not initiate in patients with stable ischemic heart disease due to an increased risk of cardiovascular complications (Fihn 2012).

• Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (fever, trauma, infection, surgery).

Other warnings/precautions:

• Appropriate use: Not indicated for use in patients with type 1 diabetes mellitus or with diabetic ketoacidosis (DKA).

• Patient education: Diabetes self-management education (DSME) is essential to maximize the effectiveness of therapy.

Metabolism/Transport Effects

Substrate of CYP2C8 (major), CYP2C9 (minor); Note: Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential

Drug Interactions

Note: Interacting drugs may not be individually listed below if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed). For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.

Abiraterone Acetate: May enhance the hyperglycemic effect of Thiazolidinediones. Risk C: Monitor therapy

Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Atazanavir: May increase the serum concentration of Rosiglitazone. Risk C: Monitor therapy

Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Antidiabetic Agents. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Cholestyramine Resin: May decrease the serum concentration of Rosiglitazone. Management: Administer rosiglitazone at least 2 hours prior to cholestyramine in order to minimize the likelihood of an interaction, and monitor patients closely for evidence of reduced rosiglitazone effectiveness. Risk D: Consider therapy modification

CYP2C8 Inducers (Moderate): May decrease the serum concentration of Rosiglitazone. Risk C: Monitor therapy

CYP2C8 Inhibitors (Strong): May increase the serum concentration of Rosiglitazone. Risk C: Monitor therapy

Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. Risk C: Monitor therapy

Inhibitors of the Proton Pump (PPIs and PCABs): May enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased. Risk C: Monitor therapy

Insulins: May enhance the adverse/toxic effect of Rosiglitazone. Specifically, the risk of fluid retention, heart failure, and hypoglycemia may be increased with this combination. Risk X: Avoid combination

Letermovir: May increase the serum concentration of Rosiglitazone. Risk C: Monitor therapy

Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C8 Substrates (High Risk with Inhibitors or Inducers). Risk C: Monitor therapy

Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Pregabalin: May enhance the fluid-retaining effect of Thiazolidinediones. Risk C: Monitor therapy

Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use. Risk C: Monitor therapy

Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Risk C: Monitor therapy

Sulfonylureas: Thiazolidinediones may enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia. Risk D: Consider therapy modification

Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents. Risk C: Monitor therapy

Vasodilators (Organic Nitrates): May enhance the adverse/toxic effect of Rosiglitazone. Specifically, a greater risk of ischemia and other adverse effects has been associated with this combination in some pooled analyses. Risk C: Monitor therapy

Reproductive Considerations

Thiazolidinediones may cause ovulation in anovulatory premenopausal patients, increasing the risk of unintended pregnancy.

Thiazolidinediones are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2021; Alexopoulos 2019; Egan 2020)

Pregnancy Considerations

Rosiglitazone crosses the placenta (Chan 2005).

Inadvertent use early in pregnancy has been reported, although in the majority of cases, the medication was stopped as soon as pregnancy was detected (Chan 2005; Kalyoncu 2005; Yaris 2004).

Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA1c should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2021; Blumer 2013).

Agents other than rosiglitazone are currently recommended to treat diabetes mellitus in pregnancy (ADA 2021).

Breastfeeding Considerations

It is not known if rosiglitazone is present in breast milk.

According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother

Dietary Considerations

Individualized medical nutrition therapy (MNT) based on American Diabetes Association recommendations is an integral part of therapy.

Monitoring Parameters

Fasting blood glucose.

HbA1c: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. Note: In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA1c is discordant with serum glucose levels or symptoms, consider evaluating HbA1c in combination with blood glucose levels and/or a glucose management indicator (ADA 2021; KDIGO 2020).

Liver enzymes (prior to initiation of therapy, then periodically thereafter); evaluate patients with ALT ≤2.5 times ULN at baseline or during therapy for cause of enzyme elevation. Patients with an elevation in ALT >3 times ULN during therapy should be rechecked as soon as possible. If the ALT levels remain >3 times ULN, therapy with rosiglitazone should be discontinued.

Signs and symptoms of fluid retention or heart failure (periodically and with dose adjustments); weight gain (periodically and with dose adjustments); ophthalmic exams (at least every 1 to 2 years, or more frequently if symptoms dictate) (ADA 2020); fractures/fracture risk.

Reference Range

Recommendations for glycemic control in patients with diabetes:

Nonpregnant adults (ADA 2021):

HbA1c: <7% (a more aggressive [<6.5%] or less aggressive [<8%] HbA1c goal may be targeted based on patient-specific characteristics). Note: In patients using a continuous glucose monitoring system, a goal of time in range >70% with time below range <4% is recommended and is similar to a goal HbA1c <7%.

Preprandial capillary blood glucose: 80 to 130 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics).

Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): <180 mg/dL (more or less stringent goals may be appropriate based on patient-specific characteristics).

Older adults (≥65 years of age) (ADA 2021):

Note: Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).

HbA1c: <7% to 7.5% (healthy); <8% to 8.5% (complex/intermediate health). Note: Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA1c level.

Preprandial capillary blood glucose: 80 to 130 mg/dL (healthy); 90 to 150 mg/dL (complex/intermediate health); 100 to 180 mg/dL (very complex/poor health).

Bedtime capillary blood glucose: 80 to 180 mg/dL (healthy); 100 to 180 mg/dL (complex/intermediate health); 110 to 200 mg/dL (very complex/poor health).

Classification of hypoglycemia (ADA 2021):

Level 1: 54 to 70 mg/dL; hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.

Level 2: <54 mg/dL; threshold for neuroglycopenic symptoms; requires immediate action.

Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.

Mechanism of Action

Thiazolidinedione antidiabetic agent that lowers blood glucose by improving target cell response to insulin, without increasing pancreatic insulin secretion. It has a mechanism of action that is dependent on the presence of insulin for activity. Rosiglitazone is an agonist for peroxisome proliferator-activated receptor-gamma (PPARgamma). Activation of nuclear PPARgamma receptors influences the production of a number of gene products involved in glucose and lipid metabolism. PPARgamma is abundant in the cells within the renal collecting tubules; fluid retention results from stimulation by thiazolidinediones which increases sodium reabsorption.

Pharmacokinetics

Onset of action: Delayed; Maximum effect: Up to 12 weeks

Distribution: Vdss (apparent): 17.6 L

Protein binding: 99.8%; primarily albumin

Metabolism: Hepatic (99%) via CYP2C8; minor metabolism via CYP2C9

Bioavailability: 99%

Half-life elimination: 3 to 4 hours; prolonged by approximately 2 hours in patients with moderate-to-severe hepatic impairment

Time to peak, plasma: 1 hour; delayed with food

Excretion: Urine (~64%) and feces (~23%) as metabolites

Pharmacokinetics: Additional Considerations

Hepatic function impairment: In moderate to severe liver disease (Child-Pugh class B or C), unbound oral Cl was significantly lower, Cmax and AUC were increased 2- and 3-fold, respectively.

Sex: Mean oral Cl in women was approximately 6% lower.

Body weight: Cl and steady-state Vd increase with increased body weight.

Pricing: US

Tablets (Avandia Oral)

2 mg (per each): $4.57

4 mg (per each): $6.78

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Brand Names: International
  • Algor (PY);
  • Avaglit (EG);
  • Avandia (AE, AR, AT, BB, BE, BG, BM, BO, BR, BS, BZ, CH, CL, CR, CZ, DE, DK, DO, EC, ET, FI, FR, GB, GR, GT, GY, HK, HN, ID, IE, IL, IT, JM, JO, KR, KW, MX, NI, NL, NO, NZ, PA, PH, PK, PL, PR, PT, RU, SA, SE, SG, SR, SV, TH, TR, TT, UY, VE, VN);
  • Diaglinex (PE);
  • Reglit (PE);
  • Rezult (IN);
  • Rosidexx (EG);
  • Rosix (CO);
  • Rosizone (TW);
  • Rovendia (TW);
  • Vidya (TW);
  • Xilan (PY)


For country code abbreviations (show table)
  1. 2019 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2019;67(4):674-694. doi:10.1111/jgs.15767 [PubMed 30693946]
  2. Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. JAMA. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981 [PubMed 31087027]
  3. Al-Salman J, Arjomand H, Kemp DG, et al. Hepatocellular Injury in a Patient Receiving Rosiglitazone. A Case Report. Ann Intern Med. 2000;132(2):121-124. [PubMed 10644273]
  4. American College of Obstetricians and Gynecologists (ACOG) practice bulletin no. 201: pregestational diabetes mellitus. Obstet Gynecol. 2018;132(6):e228-e248. doi: 10.1097/AOG.0000000000002960. [PubMed 30461693]
  5. American College of Obstetricians and Gynecologists (ACOG) Committee on Practice Bulletins—Obstetrics. ACOG Practice Bulletin No. 190: Gestational Diabetes Mellitus. Obstet Gynecol. 2018;131(2):e49-e64. [PubMed 29370047]
  6. American Diabetes Association (ADA). Standards of medical care in diabetes 2016. Diabetes Care. 2016;39(suppl 1):S1-S113. [PubMed 24357209]
  7. American Diabetes Association (ADA). Standards of medical care in diabetes–2021. Diabetes Care. 2021;44(suppl 1):S1-S232. https://care.diabetesjournals.org/content/44/Supplement_1. Accessed January 13, 2021.
  8. American Diabetes Association (ADA) Professional Practice Committee, Draznin B, Aroda VR, et al. 6. Glycemic targets: standards of medical care in diabetes-2022. Diabetes Care. 2022a;45(suppl 1):S83-S96. doi:10.2337/dc22-S006 [PubMed 34964868]
  9. American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, et al. 14. Children and adolescents: standards of medical care in diabetes-2022. Diabetes Care. 2022b;45(suppl 1):S208-S231. doi:10.2337/dc22-S014 [PubMed 34964865]
  10. Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in J Clin Endocrinol Metab. 2015;100(5):2135-2136]. J Clin Endocrinol Metab. 2015;100(2):342-362. doi:10.1210/jc.2014-3415 [PubMed 25590212]
  11. Avandia (rosiglitazone) [prescribing information]. Research Triangle Park, NC: GlaxoSmithKline; November 2020.
  12. Avandia (rosiglitazone) [product monograph]. Mississauga, Ontario: GlaxoSmithKline; October 2017.
  13. Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2013;98(11):4227-4249. [PubMed 24194617]
  14. Chan LY, Yeung JH, Lau TK. Placental Transfer of Rosiglitazone in the First Trimester of Human Pregnancy. Fertil Steril. 2005;83(4):955-958. [PubMed 15820806]
  15. Copeland KC, Zeitler P, Geffner M, et al. Characteristics of Adolescents and Youth With Recent-Onset Type 2 Diabetes: The TODAY Cohort at Baseline. J Clin Endocrinol Metab. 2011;96(1):159-167. [PubMed 20962021]
  16. Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. doi:10.2337/dci18-0033 [PubMed 30291106]
  17. DeFronzo RA. Pharmacologic Therapy for Type 2 Diabetes Mellitus. Ann Intern Med. 1999;131(4):281-303. [PubMed 10454950]
  18. Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. Mayo Clin Proc. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019 [PubMed 32736942]
  19. Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on Women's Health Aspects of Polycystic Ovary Syndrome (PCOS): The Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97(1):28-38. [PubMed 22153789]
  20. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126(25):3097-3137. [PubMed 23166211]
  21. Forman LM, Simmons DA, Diamond RH. Hepatic Failure in a Patient Taking Rosiglitazone. Ann Intern Med. 2000;132(2):118-121. [PubMed 10644272]
  22. Freid J, Everitt D, Boscia J. Rosiglitazone and Hepatic Failure. Ann Intern Med. 2000;132(2):164-166.
  23. Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. Endocr Pract. 2020;26(1):107-139. doi:10.4158/CS-2019-0472 [PubMed 32022600]
  24. Kahn SE, Haffner SM, Heise MA, et al. Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy. N Engl J Med. 2006;355(23):2427-2443. [PubMed 17145742]
  25. Kalyoncu NI, Yaris F, Ulku C, et al. A Case of Rosiglitazone Exposure in the Second Trimester of Pregnancy. Reprod Toxicol. 2005;19(4):563-564. [PubMed 15749272]
  26. Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. Kidney Int. 2020;98(supp 4):S1-S115. doi:10.1016/j.kint.2020.06.019 [PubMed 32998798]
  27. Kirkman M, Briscoe VJ, Clark N, et al. Diabetes in Older Adults: A Consensus Report. J Am Geriatr Soc. 2012;60(12):2342-2356. doi:10.1111/jgs.12035 [PubMed 23106132]
  28. LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2019;104(5):1520-1574. doi:10.1210/jc.2019-00198 [PubMed 30903688]
  29. Liu S, Huang T, Sahud MA, “Rosiglitazone-Induced Immune Thrombocytopenia,” Platelets, 2006, 17(3):143-8. [PubMed 16702039]
  30. Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic & Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. Surg Obes Relat Dis. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025 [PubMed 31917200]
  31. Melissas J, Leventi A, Klinaki I, et al. Alterations of global gastrointestinal motility after sleeve gastrectomy: a prospective study. Ann Surg. 2013;258(6):976-982. doi: 10.1097/SLA.0b013e3182774522. [PubMed 23160151]
  32. Practice Committee of American Society for Reproductive Medicine, "Use of Insulin-Sensitizing Agents in the Treatment of Polycystic Ovary Syndrome," Fertil Steril, 2008, 90(5 Suppl):S69-73. [PubMed 19007650]
  33. Shah AS, Zeitler PS, Wong J, et al. ISPAD clinical practice consensus guidelines 2022: type 2 diabetes in children and adolescents. Pediatr Diabetes. 2022;23(7):872-902. doi:10.1111/pedi.13409 [PubMed 36161685]
  34. TODAY Study Group, Zeitler P, Epstein L, et al, "Treatment Options for Type 2 Diabetes in Adolescents and Youth: A Study of the Comparative Efficacy of Metformin Alone or in Combination With Rosiglitazone or Lifestyle Intervention in Adolescents With Type 2 Diabetes," Pediatr Diabetes, 2007, 8(2):74-87. [PubMed 17448130]
  35. TODAY Study Group, Zeitler P, Hirst K, et al, "A Clinical Trial to Maintain Glycemic Control in Youth With Type 2 Diabetes," N Engl J Med, 2012, 366(24):2247-56. [PubMed 22540912]
  36. Yaris F, Yaris E, Kadioglu M, et al, "Normal Pregnancy Outcome Following Inadvertent Exposure to Rosiglitazone, Gliclazide, and Atorvastatin in a Diabetic and Hypertensive Woman," Reprod Toxicol, 2004, 18(4):619-21. [PubMed 15135857]
Topic 10249 Version 253.0